



Respiratory & Allergic Disease

INTERACTIVE CASE STUDY POST-TEST

CME Exam and Evaluation

Who is the Allergic Asthmatic?

Case 2 - Emily B.

To receive CME credit, circle the correct response, complete the requested information, and FAX the form to **973-525-1874**. Certificates will be mailed to the address listed below and please allow three weeks for processing.

This program expires 2/2007. Credit may only be received one time for this activity.

Participant Information (Please Print)

Name _____ Degree _____

Specialty _____

Institution _____

Street _____ State _____ Zip _____

City _____ Telephone _____

Signature _____

(I certify that I have completed this CME activity as designed)

Program Evaluation

Please circle the number which best reflects your opinion of the following statements, using the following rating scale:

1 = Strongly Agree; | 2 = Agree; | 3 = Disagree; | 4 = Strongly Disagree

1. The program objectives were met	1	2	3	4
2. The program content was useful and relevant	1	2	3	4
3. The program was presented in an organized manner	1	2	3	4
4. The program was unbiased and non-promotional	1	2	3	4
5. The program will change the way you practice	1	2	3	4
6. The author/faculty demonstrated expertise in the topic	1	2	3	4

Estimated time to complete this program was: _____

Program Exam

1. The average cost of a visit to the emergency department for an asthmatic patient is:
 - a. \$250
 - b. \$300-\$400
 - c. \$400-\$500
 - d. None of the above
2. Patients taking long-term high doses of _____ may experience an age-related accelerated decline in lung function as a result of airway remodeling.
 - a. leukotriene modifiers
 - b. inhaled corticosteroids
 - c. long-acting beta-agonists
 - d. theophylline
3. Omalizumab doses are determined based on _____.
 - a. the patient's body weight
 - b. the patient's IgE level
 - c. the severity of the patient's symptoms
 - d. the patient's body weight and IgE level
4. The SOLAR study, which examined the effects of omalizumab in patients with concomitant asthma and rhinitis, found that patients experienced an improvement in both asthma and rhinitis symptoms.
 - a. True
 - b. False
5. The study by Djukanović and colleagues showed that after 16 weeks of anti-IgE therapy, there was a _____ in IgE positive cells.
 - a. 10-fold reduction
 - b. 5-fold reduction
 - c. 2-fold reduction
 - d. slight reduction
6. The use of systemic or inhaled corticosteroids can be reduced gradually after approximately _____ of omalizumab therapy.
 - a. 1 month
 - b. 2 months
 - c. 4-6 months
 - d. 6-8 months
7. Data published by Burrows and colleagues found that even in patients thought to be nonatopic or nonallergic, there was an association between elevated IgE level and the presence of asthma.
 - a. True
 - b. False
8. When adding anti-IgE therapy to the regimen of patients taking inhaled corticosteroids or leukotriene modifiers, one can expect to see a response to therapy:
 - a. within 3-6 weeks
 - b. within 6-8 weeks
9. A trial period of _____ of omalizumab therapy is recommended in order to effectively evaluate a patient's response.
 - a. 3 months
 - b. 4 months
 - c. 5 months
 - d. 6 months
10. The most common adverse effect noted with omalizumab therapy is:
 - a. injection site reaction
 - b. anaphylaxis
 - c. malignancy
 - d. None of the above